Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment.

Duchenne muscular dystrophy (DMD) is caused by mutations in the gene that encodes the 427-kDa cytoskeletal protein dystrophin. Increased knowledge of the function of dystrophin and its role in muscle has led to a greater understanding of the pathogenesis of DMD. This, together with advances in the g...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Nowak, K, Davies, K
Aineistotyyppi: Journal article
Kieli:English
Julkaistu: 2004
_version_ 1826288890404667392
author Nowak, K
Davies, K
author_facet Nowak, K
Davies, K
author_sort Nowak, K
collection OXFORD
description Duchenne muscular dystrophy (DMD) is caused by mutations in the gene that encodes the 427-kDa cytoskeletal protein dystrophin. Increased knowledge of the function of dystrophin and its role in muscle has led to a greater understanding of the pathogenesis of DMD. This, together with advances in the genetic toolkit of the molecular biologist, are leading to many different approaches to treatment. Gene therapy can be achieved using plasmids or viruses, mutations can be corrected using chimaeraplasts and short DNA fragments, exon skipping of mutations can be induced using oligonucleotides and readthrough of nonsense mutations can be achieved using aminoglycoside antibiotics. Blocking the proteasome degradation pathway can stabilize any truncated dystrophin protein, and upregulation of other proteins can also prevent the dystrophic process. Muscle can be repopulated with myoblasts or stem cells. All, or a combination, of these approaches hold great promise for the treatment of this devastating disease.
first_indexed 2024-03-07T02:20:33Z
format Journal article
id oxford-uuid:a3c2bcda-02c0-42e7-996a-0a97fd19902a
institution University of Oxford
language English
last_indexed 2024-03-07T02:20:33Z
publishDate 2004
record_format dspace
spelling oxford-uuid:a3c2bcda-02c0-42e7-996a-0a97fd19902a2022-03-27T02:29:19ZDuchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a3c2bcda-02c0-42e7-996a-0a97fd19902aEnglishSymplectic Elements at Oxford2004Nowak, KDavies, KDuchenne muscular dystrophy (DMD) is caused by mutations in the gene that encodes the 427-kDa cytoskeletal protein dystrophin. Increased knowledge of the function of dystrophin and its role in muscle has led to a greater understanding of the pathogenesis of DMD. This, together with advances in the genetic toolkit of the molecular biologist, are leading to many different approaches to treatment. Gene therapy can be achieved using plasmids or viruses, mutations can be corrected using chimaeraplasts and short DNA fragments, exon skipping of mutations can be induced using oligonucleotides and readthrough of nonsense mutations can be achieved using aminoglycoside antibiotics. Blocking the proteasome degradation pathway can stabilize any truncated dystrophin protein, and upregulation of other proteins can also prevent the dystrophic process. Muscle can be repopulated with myoblasts or stem cells. All, or a combination, of these approaches hold great promise for the treatment of this devastating disease.
spellingShingle Nowak, K
Davies, K
Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment.
title Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment.
title_full Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment.
title_fullStr Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment.
title_full_unstemmed Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment.
title_short Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment.
title_sort duchenne muscular dystrophy and dystrophin pathogenesis and opportunities for treatment
work_keys_str_mv AT nowakk duchennemusculardystrophyanddystrophinpathogenesisandopportunitiesfortreatment
AT daviesk duchennemusculardystrophyanddystrophinpathogenesisandopportunitiesfortreatment